Back

Activation of prostaglandin E2 receptor 4 ameliorates pulmonary vascular remodeling and pulmonary hypertension via suppression of MEK/ERK activation

30 August 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: From vascular remodelling to ventricular dysfunction: new insights into pulmonary hypertension Hypertension, Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Keiji Kimuro

Kyushu University Graduate School of Medical Sciences, Fukuoka (Japan)

6 More presentations in this session

Presentation thumbnail
The effect of wedge pressure on the pulmonary compliance to resistance relationship
Doctor H. Kempton (Munich, DE)
Abstract Slides Video
Presentation thumbnail
CTRP7 as a molecular biomarker for predicting responsiveness to pulmonary vasodilators: insights from human and animal studies in pulmonary arterial hypertension.
Doctor K. Yamada (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Progesterone preserves eNOS coupling and supports endothelium-dependent vasodilation in the pulmonary artery of female rats: a potential therapeutic strategy for pulmonary arterial hypertension
Doctor D. Lyu (Chongqing, CN)
Abstract Slides Video
Presentation thumbnail
Single-nuclei transcriptomics uncovers right ventricular adaptation to pulmonary hypertension
Mr G. Bonazza (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
TRIB2 promotes pulmonary artery smooth muscle cell proliferation in pulmonary hypertension through SERCA2 ubiquitination
Doctor W. Zhang (Nanjing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
From vascular remodelling to ventricular dysfunction: new insights into pulmonary hypertension

The Event

Event poster

ESC Congress 2025

30 August 2025 14:15 CET
You may be interested in
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension
thumbnail
Congress Presentation
Development of KER-012, a modified ActRIIB ligand trap, for the treatment of pulmonary arterial hypertension
thumbnail
Congress Presentation
RKER-012, a novel modified ActRIIB ligand trap, attenuated right ventricular cardiomyopathy in a preclinical model of pulmonary arterial hypertension.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources